

Page 87
Notes:
conferenceseries
.com
Volume 9, Issue 9 (Suppl)
J Cancer Sci Ther, an open access journal
ISSN: 1948-5956
World Cancer 2017
October 19-21, 2017
25
th
WORLD CANCER CONFERENCE
October 19-21, 2017 | Rome, Italy
J Cancer Sci Ther 2017, 9:9(Suppl)
DOI: 10.4172/1948-5956-C1-112
Does lowvolume high-intensity interval training elicit superiorbenefits to continuous low tomoderate-
intensity training in cancer survivors?
Kellie Toohey
UCRISE, Australia
I
t is generally recommended that exercise form part of the standard of care for all cancer survivors, however, the optimal
evidence-based clinical exercise guidelines for cancer survivors are currently not clear. The aim of this study was to determine
the effectiveness of low volume high-intensity interval training (LVHIIT) and continuous low to moderate-intensity exercise
training (CLMIT) on health outcomes in cancer survivors. Sedentary cancer survivors (n=75) within 24 months of diagnosis,
aged 51±12 y were randomised into three groups for 12 weeks of LVHIIT (n=25), CLMIT (n=25) or control group (n=25). The
LVHIIT group performed 7 x 30s intervals (≥85% predicted maximal heart rate), the CLMIT group performed continuous
aerobic training for 20 min (≤55% predicted maximal heart rate) on a stationary cycle, 3 times per week. An interaction effect
(p=0.01) for waist circumference in the LVHIIT group was found. The LVHIIT group had larger improvements in emotional
well-being compared to the other groups (p<0.01). Participants in the CLMIT and LVHIIT group demonstrated improvements
in physical and functional well-being (p< 0.01). LVHIIT elicited greater benefits in improving waist circumference and
emotional well-being compared to the other groups in this study. Exercise positively impacted body composition, white blood
cell count (WBC) and haemodynamic variables, without any adverse effects. Future research should explore the mechanisms
involved in the changes reported in this study, so that clinicians can provide clinically relevant evidenced-based exercise
prescription for cancer survivors.
kellie.toohey@canberra.edu.au